skip to primary navigationskip to content

Dr Andrew Östör

Dr Andrew Östör

Consultant Rheumatologist

Director of the Rheumatology Clinical Research Unit at Addenbrooke’s Hospital

Associate Lecturer in the Faculty of Clinical Medicine

Andrew Östör is accepting applications for PhD students.

Andrew Östör is available for consultancy.

Research Interests

Currently Dr Östör’s main research interests include early inflammatory arthritis, biologic therapies and clinical trials for rheumatic diseases. He is involved with the British Society for Rheumatology’s guidelines committee and is a member of the Treat to Target initiative for RA. His other main interests include vitamin D and soft tissue disorders of the upper limb. When not at work he is either exploring a new destination or cycling around Cambridgeshire.

Over the last 10 years Dr Östör has been involved in over 50 clinical trials with a focus on biologic therapy for Rheumatoid Arthritis.


abatacept ; tofacitinib ; clinical trials ; tocilizumab ; small molecule treatment ; biologic therapy ; fostamatinib ; TNF ; anti-TNF agents ; biomarkers ; rituximab ; drug safety ; randomised control trials


  • rheumatoid arthritis
  • arthritis

Key Publications

Mäki-Petäjä KM, Elkhawad M, Cheriyan J, Joshi FR, Ostör AJ, Hall FC, Rudd JH, Wilkinson IB. Anti-Tumor Necrosis Factor-α Therapy Reduces Aortic Inflammation and Stiffness in Patients With Rheumatoid Arthritis. Circulation. 2012 Nov 20;126(21):2473-80.

Bykerk VP, Ostör AJ, Alvaro-Gracia J, Pavelka K, Ivorra JA, Graninger W, Bensen W, Nurmohamed MT, Krause A, Bernasconi C, Stancati A, Sibilia J. Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Ann Rheum Dis. 2012 May (12):1950-4.

Hadjinicolaou AV, Nisar MK, Bhagat S, Parfrey H, Chilvers ER, Ostör AJ. Non-Infectious Pulmonary Toxicity of Rituximab:a Systematic Review. Rheumatology (Oxford). 2012 Apr;51(4):653-62.

Gout T, Ostör AJ, Nisar MK. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin Rheumatol. 2011;30:1471-4. Epub 2011 Aug 11

Hadjinicolaou AV, Nisar MK, Bhagat S, Parfrey H, Chilvers ER, Ostör AJ. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review. Rheumatology (Oxford). 2011 Dec; 50(12):2297-305. Epub 2011 Oct 22

Campbell L, Chen C, Bhagat S, Parker R, Ostor AJ; Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomised controlled trials. Rheumatology (Oxford). 2011 Mar; 50(3):552-62.

Other Publications

The Rheumatology Academy 3rd-4th March 2016.

Click here to access Rheumatology Academy agenda.